Felbamate Tablets USP 400 mg and 600 mg Before prescribing felbamate, the physician should be thoroughly familiar with the details of this prescribing information. FELBAMATE SHOULD NOT BE USED BY PATIENTS UNTIL THERE HAS BEEN A COMPLETE DISCUSSION OF THE RISKS AND THE PATIENT, PARENT, OR GUARDIAN HAS BEEN PROVIDED THE FELBAMATE WRITTEN ACKNOWLEDGEMENT (SEE PATIENT/PHYSICIAN ACKNOWLEDGMENT FORM).

Patient Home

Welcome to Health Vidya. Discover trusted care and your own health — all in one place.

Felbamate Tablets USP 400 mg and 600 mg Before prescribing felbamate, the physician should be thoroughly familiar with the details of this prescribing information. FELBAMATE SHOULD NOT BE USED BY PATIENTS UNTIL THERE HAS BEEN A COMPLETE DISCUSSION OF THE RISKS AND THE PATIENT, PARENT, OR GUARDIAN HAS BEEN PROVIDED THE FELBAMATE WRITTEN ACKNOWLEDGEMENT (SEE PATIENT/PHYSICIAN ACKNOWLEDGMENT FORM).

Medication label

Why this: Advisory · dailymed-prescription

Felbamate Tablets USP are not indicated as a first line antiepileptic treatment (see WARNINGS ). Felbamate Tablets USP are recommended for use only in those patients who respond inadequately to alternative treatments and whose epilepsy is so severe that a substantial risk of aplastic anemia and/or liver failure is deemed acceptable in light of the benefits conferred by its use. If these criteria are met and the patient has been fully advised of the risk, and has provided written acknowledgement, Felbamate Tablets USP can be considered for either monotherapy or adjunctive therapy in the treatment of partial seizures, with and without generalization, in adults with epilepsy and as adjunctive therapy in the treatment of partial and generalized seizures associated with Lennox-Gastaut syndrome in children.

generic_name: felbamate
product_names: Felbamate
ndc: 72162-1770, 62559-730, 72162-1770-1
group: drugs
license: us-gov-pd
attribution: Courtesy of the National Library of Medicine
reviewed: 2026-09-18
language: en